GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Genpharmasec Ltd

Genpharmasec Ltd: No Deviation in Rights Issue Fund Utilization

FUNDRAISE ● No Immediate Change LOW RISK
📅 Filed on BSE: 03 Nov 2026, 05:46 PM IST  ·  BSE ID: e5d58714-3c88-437d-a51f-3eab0a5d87b1
View Original BSE Filing (PDF)
💡
In Simple Terms
Genpharmasec Ltd stated that money raised from its recent share offering was used exactly as planned, with no changes reported.
🤖 AI Summary
  • Genpharmasec Ltd confirmed no deviation in Rights Issue fund utilization for Q2 FY27.
  • Rs. 4,845.05 Lakhs raised on February 21, 2024, was used as per Letter of Offer.
  • Allocations included subsidiary acquisition, debt repayment, working capital, and general purposes.
  • Audit Committee reviewed and found no issues with fund utilization in the period.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Amount Raised (Rs. In Lakhs)
Rs. 4,845.05
Date of Raising Funds
21st February, 2024
Report filed for Quarter ended
September 30, 2026
Original Object - To acquire Equity Shares
Rs. 1443.58 Lakhs
Original Object - To repay or prepay Borrowings
Rs. 588.00 Lakhs
Original Object - To part finance working capital
Rs. 1650.00 Lakhs
Original Object - To Meet General corporate purposes
Rs. 1138.47 Lakhs
Original Object - To meet expenses of the Issue
Rs. 25.00 Lakhs
🏢 How This Affects the Company
📈
Business Impact
Confirms adherence to previously disclosed fund utilization plans, maintaining transparency with investors regarding the application of Rights Issue proceeds.
💰
Financial Impact
No immediate financial impact, but confirms that the company is managing its finances according to its stated objectives for the Rights Issue funds.
⚠️
Risk Impact
Reduces risk associated with potential misuse or misallocation of funds, thereby enhancing investor confidence in financial stewardship.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders regarding this filing.
👤
Who Is Affected
All shareholders are informed of the company's adherence to its stated fund utilization plans for the Rights Issue.
🔍
Management Signal
This filing signals management's commitment to transparency and compliance with SEBI regulations regarding fund utilization.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Next quarter's results for Q3 FY27 fund utilization update.
Annual report for comprehensive review of fund deployment.
Future corporate announcements for strategic fund allocation.
LOW RISK Filing is a routine compliance update, confirming no deviation in fund utilization as per regulations.
💡 Investor Takeaway
Genpharmasec Ltd confirmed no deviation in the use of Rs. 4,845.05 Lakhs from its Rights Issue for the quarter ended September 30, 2026, as reviewed by the Audit Committee.
⚖️ Strengths & Concerns

✅ Positives

  • Confirmation of no deviation in the utilization of Rs. 4,845.05 Lakhs raised via Rights Issue.
  • Audit Committee review found no concerns regarding the application of funds as per stated objectives.
❓ Frequently Asked Questions
Did Genpharmasec Ltd deviate from its Rights Issue fund utilization plans for Q2 FY27?
No, Genpharmasec Ltd confirmed there was no deviation or variation in the use of proceeds from its Rights Issue for the quarter ended September 30, 2026.
What was the total amount raised by Genpharmasec Ltd via its Rights Issue?
Genpharmasec Ltd raised Rs. 4,845.05 Lakhs through its Rights Issue, which was allotted on February 21, 2024.
What were the original objects for which Genpharmasec Ltd raised funds?
The funds were originally intended for acquiring equity shares, repaying borrowings, financing working capital, general corporate purposes, and meeting issue expenses.
Was the use of Rights Issue funds reviewed by Genpharmasec Ltd's Audit Committee?
Yes, the statement of no deviation in fund utilization was duly reviewed by the Audit Committee of Genpharmasec Ltd.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again — explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.